Chronic Pain Clinical Trial
Official title:
High Level Pulsed Heat Versus Low Level Steady Heat in Subjects With Chronic Low Back Pain
This study is a double blinded randomized active placebo controlled trial in subjects with chronic low back pain. The trial compares pain relief by a device that delivered high level pulsed heat (45 °C) to pain relief delivered by a steady heat lower temperature device (37 °C). The hypothesis is that the high temperature pulsed heat device will produce significantly better pain relief as compared to the lower level steady heat device. The secondary hypothesis is that pain relief will occur faster in the high pulsed heat device as compared to the control device.
1. This study will be conducted under Good Clinical Practice (GCP) guidelines and suitable
for FDA submission in order to obtain claims such as, "provides temporary pain relief
for people with chronic lower back pain."
2. The study is designed as a randomized double blinded two arm placebo controlled trial.
3. The active arm (N=50) receives two active Series 5 heating units (Soovu Labs Inc.) that
pulse heat to 45ºC (113ºF). The active Series 5 placebo arm (N=50) gets two identical
appearing units (Soovu Labs Inc.) that produce low level of heat at 37ºC (96.8 ºF). For
reference skin temperature is about 33 ºC and room temperature 23 ºC.
4. The study hypothesis is that in subjects with chronic low back pain, the active heating
device group will show a statistical improvement in pain scores as compared to the
active placebo group as measured by the primary outcome measure, the Numeric Pain Scale
(NPS).
5. Subjects will be told the study is examining the pain relieving effectiveness of two
different levels of heat.
6. Subjects must have chronic low back pain with a pretreatment level of pain 4 or greater
on a 0-10 point scale. By definition chronic low back pain is a condition that has been
present for at least 6 months and must be present more days than not over the course of
a week.
7. No use of pain medications during the four hour trial. However, pain medications
including schedule IIIs can be taken up to 30 minutes before the start of the trial.
Medications permitted during the trial include medications such as tramadol, codeine,
NSIADs, gabapentin and acetaminophen. Non-pain medications for medical indications are
permitted at any time. Subjects taking schedule II opioids are excluded from the study.
Schedule II opioids include oxycodone, hydromorphone, hydrocodone, fentanyl and
methadone.
8. Ages 22 through 70 inclusive.
9. Exclusion criteria- sciatica if present must be rated significantly less than the non
-radiating component of the low back pain, pregnancy, skin lesions such as open skin or
sores, scar tissue, skins grafts, old burns over the treatment area or neuropathic
sensory loss over the treatment site.
10. Pre-treatment assessments include, Numeric Pain Scale, and a pre-study questionnaire
(history, treatment preferences, short form Brief Pain Inventory, and short form
Magill).
11. Each treatment session lasts approximately 30 minutes with pain assessments throughout
using NPS (primary outcome measure). Secondary outcome measures include measures of
comfort and willingness to endorse their treatment.
12. All subjects are followed for a 4 hour post treatment period with intermittent pain
assessments (NPS).
13. At the end of the post treatment period, subjects complete a post study usability
questionnaire and a blinding questionnaire.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|